Navigation Links
Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
Date:3/12/2008

March 12, 2008 (BRONX, NY) The unwanted activation of an important cell-signaling pathway may play a role in two kidney problems that are major causes of end-stage renal disease, scientists at the Albert Einstein College of Medicine of Yeshiva University have found. Their research, which opens up a novel approach for treating kidney failure, is described in the March issue of Nature Medicine. The study was led by Dr. Katalin Susztak, an assistant professor of medicine (nephrology) at Einstein.

The kidneys filter waste products from the blood and maintain the bodys fluid balance by producing urine. The filtration is carried out by numerous capillary tufts within the kidney known as glomeruli. Kidney disease occurs when glomeruli become damaged and can no longer perform their filtering function. Kidney damage may ultimately progress to end-stage renal disease, in which patients need dialysis or a kidney transplant.

The Einstein scientists focused on cells known as podocytes that line the glomeruli. Since dysfunction of podocytes cells is important in progressive kidney disease, and since a cell-signaling pathway called Notch is crucial in podocyte development, the Einstein researchers reasoned that aberrant Notch signaling might play a role in causing kidney disease.

The Notch signaling pathway plays a key role in embryonic development of humans and most other multicellular organisms. The Notch pathway tells some cells to proliferate and others to undergo programmed cell death as it profoundly affects the way tissues are organized. Faulty Notch signaling has been found in several types of cancer and in many other diseases such as multiple sclerosis.

Collectively, the observations made in the Einstein study offer strong evidence that aberrant Notch signaling is also involved in diabetic nephropathy (DNP) and focal segmental glomerulosclerosis (FSGS)two of the major causes of end-stage renal disease. For example:

    '/>"/>


Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
2. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
3. USC researchers discover novel way to develop tumor vaccines
4. Novel mechanism found that may boost impaired function of leukemia protein
5. Novel method to reveal drug targets
6. Novel link between excessive nutrient levels and insulin resistance
7. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
8. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
9. Novel approach strips staph of virulence
10. UCSD research team identifies novel anticancer drug from the sea
11. Novel compound may lessen heart attack damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ced Acquisition in 2009 Continues Growth Trend , ...rstCall/ -- IPC The Hospitalist Company, Inc. (Nas...ician group practice company, announced today that...st Acute Care Consultants, Inc. (MACC) in St. Loui...expansion in the St. Louis market, where IPC has e...
(Date:1/8/2009)...Jan. 8 The Pew Charitab...een named director, chemical and food safety progr...gram. Olson, who was formerly deputy staff directo...nvironment and Public Works, brings nearly 25 year...er advocacy to Pew. , , "We are excited to be ...
(Date:1/8/2009)... Jan. 8 Cephalon, Inc ....ino, Jr., Ph.D., Chairman and CEO will present at... on January 13, 2009 in San Francisco, CA at appro...me). The presentation will be webcast live on the ...e. , , The webcast will be archived for one we...
(Date:1/8/2009)...lo., Jan. 8 Heska Corpor...bcast: , , , What: Heska Corporation I... Year-End 2008 Earnings Conference Call on t...:00 a.m. (MST], Where: www.heska.com (cli... Call link on the front page of this website)....
Breaking Medicine News(10 mins):Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2
...nvolving more than 65, 000 persons show a positi... the risk of developing cancer//. Dr. Par Stattin...m, who examined data from 31,304 men and 33,293 wo...cts had previously participated in a larger study...
...change in health caused by an unintentional injury... are more likely to have difficulty// obtaining re...ce larger declines in short-term health, according...he Urban Institute, Washington, D.C., presented th...
...le phones when the ban on them gets lifted shortly...s because it was believed// that its electromagnet...al equipments. But as per the directive issued fro...d everywhere excepting near a few specialist equip...
...om the Centers for Disease Control// and Preventio...atistics have decreased significantly in their cou... this mainly to routine hepatitis immunizations, i...reports that more than 100,000 Americans were infe...
Other Medicine News:Health News:Beware of High Sugar Levels Even If You are Not Diabetic 2Health News:Uninsured Often Receive Less Medical Care 2Health News:Hepatitis Rates Plummet in the U.S 2
(Date:1/7/2009)...tan Puhua Hospital Stem Cells Center ( http://www....g stem cells to effectively treat neurological dis...ed additions to its medical and research staff tha...pabilities for growing numbers of incoming interna...e distinguished Dr. Jiang Ping, who was named Chie...
(Date:1/6/2009)...ire/ -- The Michael J. Fox Foundation awarded a to...h teams for pre-clinical research on potential new...nding was awarded under the Foundation,s Therapeu...launched in 2006, supports and bolsters industry-f...art of MJFF,s focus on ,de-risking, preclinical ...
(Date:1/5/2009)...lene Pharmaceuticals announced today that it has i...protein kinase inhibitor, CX-4945, in patients wit...ultiple myeloma. The primary endpoints of the oral..., tolerance and PK properties of CX-4945 and to se...addition, multiple mechanism-related pharmacodynam...
(Date:12/29/2008)...SNewswire/ -- The winner of the 2008 Award for Exc... today by Dr. Peter G. Goldschmidt, President and ..., The winner of the annual award was the Unive...or its best practice " IND Regulatory and Monitori...d human subjects protection, 2) improved data qual...
Breaking Medicine Technology:Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2Few Employers Addressing Workplace Stress Watson Wyatt Surveys Find 11948 1Few Employers Addressing Workplace Stress Watson Wyatt Surveys Find 11948 2Few Employers Addressing Workplace Stress Watson Wyatt Surveys Find 11948 3Strategy for nanotechnology related environmental health and safety research 2209 1Strategy for nanotechnology related environmental health and safety research 2209 2IAEA helps recover stray radioactive sources in Nigeria 2204 1IAEA helps recover stray radioactive sources in Nigeria 2204 2DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 11941 1DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 11941 2DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 11941 3
...r 18, 2007 - Nymox,Pharmaceutical Corporation (NAS...month follow-up study of NX-1207 for benign,prosta...atic,progress of U.S. patients involved in the Com...dividuals in the study were assessed,for symptomat... of,efficacy. Patients in the study were assessed ...
...WIRE)--Apr 17, 2007 -,Seattle Genetics, Inc. (Nasd...tations by the company and its collaborators at th...for Cancer Research,(AACR) demonstrating preclinic...jugate (ADC) technology and cancer product,pipelin...killing drugs.,Seattle Genetics, ADC technology em...
Other Medicine Technology:Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH 2Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR 2Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR 3Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR 4
If you prefer a standard style iridectomy lens, then consider the Volk Iridectomy Lens. Its 8mm imaging bulb delivers the view you're used to but with the added benefit of Volk's exclusive Double Asp
...d Super Macula® 2.2 offers extremely high reso...vea, while achieving an exceptionally wide 78°...or critical evaluation of the optic nerve head and...f the macula and disc. Redesigned to reduce weight...
...Equator is designed for focal laser therapy and mi...ptical design presents a realistic contour of the ...ld view of the entire posterior pole extending to ...ws dynamic movement on the globe, therefore increa...
...0x Imaging Lens is optimized for the visible spect...ns during general diagnosis and slit lamp imaging....posterior pole and a sharper image across the diam...s also ideal for slit lamp photography. For best r...
Medicine Products: